Norpipanone:

Phenadoxone;

Phenampromide:

Phenomorphan;

**56** 

57

58 59 HB280

```
005235946
                                           HOUSE BILL NO. 280
 1
 2
3
4
5
6
7
                            AMENDMENT IN THE NATURE OF A SUBSTITUTE
                             (Proposed by the Senate Committee for Courts of Justice
                                              on March 5, 2000)
                                   (Patron Prior to Substitute—Delegate Suit)
     A BILL to amend and reenact §§ 54.1-3446 and 54.1-3450 of the Code of Virginia, to amend the Code
        of Virginia by adding a section numbered 18.2-251.3, relating to drug schedules; possession of a
        "date rape" drug; penalties.
 8
 9
        Be it enacted by the General Assembly of Virginia:
    1. That §§ 54.1-3446 and 54.1-3450 of the Code of Virginia are amended and reenacted, and that
10
    the Code of Virginia is amended by adding a section numbered 18.2-251.3 as follows:
11
12
        § 18.2-251.3. Possession and distribution of gamma-butyrolactone; 1, 4 - butanediol; ; enhanced
13
    penalty.
14
       Any person who knowingly manufactures, sells, gives, distributes or possesses with the intent to
15
    distribute the substances gamma-butyrolactone; or 1, 4 - butanediol, when intended for human
    consumption shall be guilty of a Class 3 felony.
16
        § 54.1-3446. Schedule I.
17
18
        The controlled substances listed in this section are included in Schedule I:
19
        1. Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers,
20
    esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers
21
    and salts is possible within the specific chemical designation:
22
        Acetylmethadol;
23
        Allylprodine:
        Alphamethylfentanyl:
24
25
        Alphacetylmethadol (except levo-alphacetylmethadol, also known as levo-alpha-acetylmethadol,
26
    levomethadyl acetate, or LAAM);
        Alphameprodine;
27
28
        Alphamethadol;
29
        Benzethidine;
30
        Betacetylmethadol;
31
        Betameprodine;
32
        Betamethadol;
33
        Betaprodine;
34
        Clonitazene:
35
        Dextromoramide:
36
        Diampromide;
37
        Diethylthiambutene;
        Difenoxin;
38
39
        Dimenoxadol:
40
        Dimepheptanol;
        Dimethylthiambutene;
41
42
        Dioxaphetylbutyrate;
        Dipipanone;
43
        Ethylmethylthiambutene;
44
45
        Etonitazene:
        Etoxeridine:
46
        Furethidine:
47
48
        Hydroxypethidine;
49
        Ketobemidone:
50
        Levomoramide:
51
        Levophenacylmorphan;
52
        Morpheridine:
53
        Noracymethadol:
54
        Norlevorphanol;
55
        Normethadone;
```

HB280S1 2 of 5

```
60
         Phenoperidine:
         Piritramide;
 61
 62
         Proheptazine;
 63
         Properidine;
 64
         Propiram;
 65
         Racemoramide:
 66
         Trimeperidine.
 67
         2. Any of the following opium derivatives, their salts, isomers and salts of isomers, unless
 68
      specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible
      within the specific chemical designation:
 69
 70
         Acetorphine;
 71
         Acetyldihydrocodeine;
 72
         Benzylmorphine;
 73
         Codeine methylbromide;
         Codeine-N-Oxide;
 74
 75
         Cyprenorphine;
 76
         Desomorphine:
 77
         Dihydromorphine;
 78
         Drotebanol;
 79
         Etorphine;
 80
         Heroin;
 81
         Hydromorphinol;
 82
         Methyldesorphine:
         Methyldihydromorphine:
 83
 84
         Morphine methylbromide:
 85
         Morphine methylsulfonate;
         Morphine-N-Oxide;
 86
 87
         Myrophine;
 88
         Nicocodeine:
 89
         Nicomorphine;
 90
         Normorphine:
 91
         Phoclodine;
 92
         Thebacon.
 93
         3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture,
      or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers,
 94
 95
 96
      and salts of isomers is possible within the specific chemical designation (for purposes of this subdivision
 97
      only, the term "isomer" includes the optical, position, and geometric isomers):
         Alpha-ethyltryptamine (some trade or other names: Monase;a-ethyl-1H-indole-3-ethanamine;
 98
 99
      3-[2-aminobutyl] indole; a-ET; AET);
100
         4-Bromo-2,5-dimethoxyphenethylamine (some
                                                                            trade or
                                                                                           other
101
      2-[4-bromo-2,5-dimethoxyphenyl]-1-aminoethane; alpha-desmethyl DOB; 2C-B; Nexus);
102
         3,4-methylenedioxy amphetamine;
103
         5-methoxy-3,4-methylenedioxy amphetamine;
         3,4,5-trimethoxy amphetamine;
104
         Bufotenine;
105
         Diethyltryptamine;
106
         Dimethyltryptamine;
107
         4-methyl-2,5-dimethoxyamphetamine;
108
109
         2,5-dimethoxy-4-ethylamphetamine (DOET);
110
         Ibogaine;
         Lysergic acid diethylamide;
111
112
         Mescaline;
         Parahexyl (some trade or other names: 3-Hexyl-1-hydroxy-7, 8, 9, 10-tetrahydro-6, 6,
113
114
      9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl);
115
         Pevote:
116
         N-ethyl-3-piperidyl benzilate;
         N-methyl-3-piperidyl benzilate;
117
         Psilocybin;
118
         Psilocvn:
119
```

Tetrahydrocannabinols, except as present in marijuana and dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the U.S. Food and Drug Administration;

- Hashish oil (some trade or other names: hash oil; liquid marijuana; liquid hashish);
- 2,5-dimethoxyamphetamine (some trade or other names: 2,5-dimethoxy-a-methylphenethylamine; 2,5-DMA);
  - 3,4-methylenedioxymethamphetamine (MDMA), its optical, positional and geometric isomers, salts and salts of isomers;
  - 3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-alpha-methyl-3,4 (methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA);
  - 4-bromo-2,5-dimethoxyamphetamine (some trade or other names 4-bromo-2,5-dimethoxy-a-methylphenethylamine; 4-bromo-2,5-DMA);
  - 4-methoxyamphetamine (some trade or other names: 4-methoxy-a-methylphenethylamine; paramethoxyamphetamine; PMA);

N-ethyl analog of phencyclidine;

Pyrrolidine analog of phencyclidine;

Thiophene analog of phencyclidine.

4. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

gamma hydroxybutyric acid (some other names include GHB; gamma hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate)

Mecloqualone;

125

126

127

128

129

130

131

132

133

134

135

136 137

138

139

140

141

142

143

144

145

146

147 148

149

150

151

152

153

154

155

156

157 158

159

160

161

162 163

164

165

166

167

168 169

**170** 

171

172

173

174

175

176 177

178

179

180

181

Methaqualone.

5. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:

Aminorex (some trade or other names; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; 4, 5-dihydro-5-phenyl-2-oxazolamine);

Fenethylline;

Ethylamphetamine;

Cathinone (some trade or other names: 2-amino-1-phenyl-1-propanone, alpha-aminopropiophenone, 2-aminopropiophenone, norephedrone), and any plant material from which Cathinone may be derived;

Methcathinone (some other names: 2-(methylamino)-propiophenone; alpha-(methylamino) propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR 1432).

- 6. Any material, compound, mixture or preparation containing any quantity of the following substances:
- 3-methylfentany-(N-[3-methyl -1- (2-phenyethyl) -4- piperidyl] N-phenylpropanamide), its optical and geometric isomers, salts, and salts of isomers;

1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers, salts and salts of isomers;

- 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (PEPAP), its optical isomers, salts and salts of isomers;
- N-[1-(1-methyl-2-phenyl)ethyl-4-piperidyl]-N-phenylacetamide (acetyl-alpha-methylfentanyl), its optical isomers, salts and salts of isomers;
- N-[1-(1-methyl-2-2-thienyl)ethyl-4 piperidyl]-N-phenylpropanamide (alpha-methylthiofentanyl), its optical isomers, salts and salts of isomers;
- N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts and salts of isomers;
- N-[1-(2-hydroxy-2-phenyl) ethyl-4-piperidyl]-N-phenylpropanamide (beta-hydroxyfentanyl), its optical isomers, salts and salts of isomers;
- N-[3-methyl-1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl]-N-phenylpr opanamide (beta-hydroxy-3-methylfentanyl), its optical and geometric isomers, salts and salts of isomers;
- N-[3-methyl-1-(2-2-thienyl)ethyl-4-piperidyl]-N-phenylpropanami de (3-methylthiofentanyl), its optical and geometric isomers, salts and salts of isomers;
- N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide(thenylf entanyl), its optical isomers, salts and salts of isomers;
- N-[1-(2-2-thienyl)ethyl-4-piperidyl]-N-phenylpropanimide(thiofe ntanyl), its optical isomers, salts and salts of isomers.
  - § 54.1-3450. Schedule III.
  - The controlled substances listed in this section are included in Schedule III:
- 182 1. Unless specifically exempted or listed in another schedule, any material, compound, mixture, or

HB280S1 4 of 5

preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules;

Any compound, mixture or preparation containing amobarbital, secobarbital, or pentobarbital or any salt of amobarbital, secobarbital, or pentobarbital and one or more other active medicinal ingredients which are not listed in Schedules II through V;

Any suppository dosage form containing amobarbital, secobarbital, or pentobarbital or any salt of amobarbital, secobarbital, or pentobarbital and approved by the Food and Drug Administration for marketing only as a suppository;

Chlorhexadol;

Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act;

Lysergic acid;

Lysergic acid amide;

Methyprylon;

200 Sulfondiethylmethane;

Sulfonethylmethane;

202 Sulfonmethane:

Tiletamine - zolazepam or any salt thereof;

Nalorphine.

2. Any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:

Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts:

Not more than 300 milligrams of dihydrocodeinone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;

Not more than 300 milligrams of dihydrocodeinone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

Not more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

Not more than 300 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more ingredients in recognized therapeutic amounts;

Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

Not more than 50 milligrams of morphine, or any of its salts, per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

Benzphetamine;

Chlorphentermine;

Clortermine;

Phendimetrazine.

- 4. The Board may except by regulation any compound, mixture, or preparation containing any stimulation or depressant substance listed in subdivision 1 from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.
- 5. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts

- 245 of isomers whenever the existence of such salts of isomers is possible within the specific chemical 246 designation: 247 Anabolic steroids, including, but not limited to: 248 Boldenone (Dehydrotestosterone); 249 Clostebol (4-Chlorotestosterone) (Chlorotestosterone); 250 Dromostanolone (Drostanolone); 251 Ethylestrenol; 252 Fluoxymesterone;
- 253 Formyldienolone (Formebolone);254 Mesterolone;
- 255 Methandriol (methylandrostenediol);
- 256 Methandrostenolone (Methandienone) (Dehydromethyltestosterone);
- 257 Methenolone;
- 258 17-Methyltestosterone (Methyltestosterone);
- 259 Mibolerone;
- 260 Nandrolone (19-Nortestosterone);
- 261 Norethandrolone;
- 262 Oxandrolone;
- 263 Oxymesterone (Oxymestrone);
- 264 Oxymetholone (Anasterone);
- 265 Stanolone (4-Dihydrotestosterone) (Dihydrotestosterone);
- 266 Stanozolol (Androstanazole);
- **267** Testolactone (1-Dehydrotestololactone);
- 268 Testosterone;

271

272

273

274

275

276

Trenbolone (Trienbolone) (Trienolone); and Any salt, ester, or isomer of a drug or sult

Any salt, ester, or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. However, such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the United States Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes any such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this subdivision.

277 2. That the provisions of this act may result in a net increase in periods of imprisonment in state correctional facilities. Pursuant to § 30-19.1:4, the estimated amount of the necessary appropriation

279 is \$0 in FY 2010.